Other publications studying long-term H treatment in metastatic, locally advanced, or relapsed HER2-positive breast cancer also reported low risk of cardiac AEs and continued response [3, 14–16]; nevertheless, there remains a need for more information about patients with long-term H treatment, as reported by the ROP Study. This evidence concerns the gene ERBB2 and retinopathy of prematurity.